|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **Treatment contrasta** |  | **One-year all-****cause mortality****(N=27,184)b** |
|  **N** | **Laparoscopic surg.****(N=29,687)** |  | **Chemotherapy****(N=26,209)** |  | **FOLFOX****(N=7,594)** |  |
| **Chrischilles** |  |  |  |  |  |  |  |  |
|  0 indicators  | 15,425 | 1.00  |  | 1.00  |  | 1.00  |  | 1.00  |
|  1 indicator | 8,275 | 1.04 (0.99, 1.08) |  | **0.97 (0.94, 0.99)** |  | 0.99 (0.95, 1.04) |  | **1.18 (1.09, 1.28)** |
|  2+ indicators | 5,987 | **0.89 (0.84, 0.94)** |  | **0.87 (0.83, 0.91)** |  | **0.92 (0.85, 0.99)**  |  | **1.45 (1.34, 1.58)** |
| **Faurot** |  |  |  |  |  |  |  |  |
|  Low  | 15,426 | 1.00 |  | 1.00 |  | 1.00 |  | 1.00 |
|  Intermediate  | 8,274 | **0.84 (0.80, 0.88)** |  | **0.85 (0.82, 0.88)** |  | **0.87 (0.81, 0.92)** |  | **1.66 (1.53, 1.81)** |
|  High  | 5,987 | **0.72 (0.67, 0.77)** |  | **0.54 (0.50, 0.59)** |  | **0.68 (0.59, 0.79)** |  | **2.23 (2.02, 2.47)** |
| **Davidoff** |  |  |  |  |  |  |  |  |
|  Low  | 15,426 | 1.00 |  | 1.00 |  | 1.00 |  | 1.00 |
|  Intermediate  | 8,139 | **0.82 (0.78, 0.85)** |  | **0.90 (0.88, 0.93)** |  | **0.94 (0.90, 0.98)** |  | **1.22 (1.13, 1.32)** |
|  High | 6,122 | **0.72 (0.68, 0.76)** |  | **0.75 (0.72, 0.79)** |  | **0.83 (0.77, 0.89)** |  | **1.66 (1.54, 1.79)** |
| **Segal** |  |  |  |  |  |  |  |  |
|  Low  | 15,323 | 1.00 |  | 1.00 |  | 1.00 |  | 1.00 |
|  Intermediate  | 8,432 | 0.97 (0.92, 1.02) |  | **0.83 (0.79, 0.87)** |  | **0.76 (0.70, 0.82)** |  | **1.60 (1.45, 1.76)** |
|  High | 5,932 | **0.88 (0.81, 0.95)** |  | **0.61 (0.56, 0.67)** |  | **0.55 (0.46, 0.67)** |  | **1.87 (1.65, 2.11)** |

a Adjusted for stage, sex, age (<75, 75-84, 85+), race (White non-Hispanic, Black non-Hispanic, Hispanic, Other), and Gagne comorbidity score (continuous).

b Adjusted for stage, sex, age (<75, 75-84, 85+), race (White non-Hispanic, Black non-Hispanic, Hispanic, Other), and Gagne comorbidity score (<0, 0, 1, 2, 3, 4+).